Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for XmAb412 (TL1A/IL23p19 Bispecific) in Inflammatory Bowel Disease. The expected timing is based on the latest available company guidance and may change.
01/08/26:- Lead TL1A x IL23p19 bispecific; preclinical characterization in H1 2026; first-in-human study planned H2 2026. 02/26/26:- On track for XmAb412 preclinical DDW poster May 2026 and first-in-human study initiation in H2 2026. 05/04/26:- First-in-human healthy participant study expected to begin in Q3 2026. 05/06/26:- Preclinical data showed dual TL1A and IL-23 pathway suppression; first-in-human study initiation remains on track for 3Q26. 08/05/26:- Phase 1 study opened; initial healthy participant data planned in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.